SINGAPORE, September 16, 2022 /PRNewswire/ — CellResearch Corporation Pte Ltd., a SingaporeThe New York-based biopharmaceutical company today announced that it has successfully completed the first Phase I study of CorLiCyte®stem cell therapy derived from umbilical cord stem cells, with research partners at University of ColoradoAnschutz Medical Campus and ClinImmune Cell and Gene Therapy.
CorLiCyte® is being developed for the treatment of a number of serious conditions, with an initial target indication for the treatment of diabetic foot ulcer (DPU). In the study protocol, nine patients with chronic DFU were treated with CorLiCyte® twice a week for 8 weeks. None of the patients in the study experienced any treatment-related adverse events and all subjects experienced a reduction in wound size over the treatment period.
“These results are encouraging and can be used to support further research with CorLiCyte® in future studies, with the potential to address unmet medical needs in the treatment of patients with chronic DFU. ” said Cecilia Low-Wangthe lead investigator of University of ColoradoAnschutz Medical Campus.
CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord stem cells, with optimized proprietary expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions. In addition to DFU, CRC is pursuing a range of potential pre-clinical indications such as osteoarthritis, venous leg ulcers, chronic inflammatory and autoimmune diseases.
About CellResearch Corporation
CellResearch Corporation (CRC) was founded in 2002 as a contract research provider focused on skin cells. In 2004, the company discovered that the lining of the umbilical cord of mammals was an abundant source of mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and has the rights to commercialize this technology in most major world markets.
CellResearch Consumer Health (formerly known as CALECIM® Cosmeceuticals) is a wholly owned subsidiary of CRC and produces an innovative line of skin and hair care products using umbilical cord stem cells to power its products. It is used in medical hair and aesthetic clinics for in-office treatments and as part of an at-home anti-aging skin care regimen. It is distributed worldwide by over 600 aesthetic doctors and online through its own website. It has a key distribution partnership with Menarini Group through South East Asia.
A partner of the CRC, Cordlife offers parents the option of storing their child’s umbilical cord tissue along with their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue in the world. As cell therapies enter the clinic, Cordlife will have the ability to grow stem cells from a banked umbilical cord for autologous and donor-related uses.
Business development and investor relations:
Tel: +65 8815 6139
Email: [email protected]